First Time Loading...

Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 2.73 USD 0.37% Market Closed
Updated: Apr 28, 2024
Section:
 

Wall Street
Price Targets

ABUS Price Targets Summary
Arbutus Biopharma Corp

Wall Street analysts forecast ABUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABUS is 4.49 USD with a low forecast of 4.04 USD and a high forecast of 5.25 USD.

ABUS Lowest Forecast
Wall Street Target
4.04 USD
48% Upside
ABUS Average Forecast
Wall Street Target
4.49 USD
64% Upside
ABUS Highest Forecast
Wall Street Target
5.25 USD
92% Upside
Lowest
Price Target
4.04 USD
48% Upside
Average
Price Target
4.49 USD
64% Upside
Highest
Price Target
5.25 USD
92% Upside
Arbutus Biopharma Corp Competitors:
Price Targets
BCYC
Bicycle Therapeutics PLC
94% Upside
MRKR
Marker Therapeutics Inc
197% Upside
ACHV
Achieve Life Sciences Inc
336% Upside
CNTA
Centessa Pharmaceuticals PLC
56% Upside
BCYC
Bicycle Therapeutics PLC
94% Upside
MRKR
Marker Therapeutics Inc
197% Upside
ACHV
Achieve Life Sciences Inc
336% Upside
CNTA
Centessa Pharmaceuticals PLC
56% Upside
M
MLYS
Mineralys Therapeutics Inc
191% Upside
ABOS
Acumen Pharmaceuticals Inc
312% Upside
KRRO
Korro Bio Inc
111% Upside
IVA
Inventiva SA
274% Upside

Revenue
Forecast

Revenue Estimate
Arbutus Biopharma Corp

For the last 8 years the compound annual growth rate for Arbutus Biopharma Corp's revenue is -3%. The projected CAGR for the next 3 years is -12%.

-3%
Past Growth
-12%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Arbutus Biopharma Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Arbutus Biopharma Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
What are analyst estimates?

See Also

Summary
ABUS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABUS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABUS stock valuation using valuation multiples.
Wall Street Estimates
ABUS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABUS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABUS's stock price target?
Price Target
4.49 USD

According to Wall Street analysts, the average 1-year price target for ABUS is 4.49 USD with a low forecast of 4.04 USD and a high forecast of 5.25 USD.

What is Arbutus Biopharma Corp's Revenue forecast?
Projected CAGR
-12%

For the last 8 years the compound annual growth rate for Arbutus Biopharma Corp's revenue is -3%. The projected CAGR for the next 3 years is -12%.

ALPHA SPREAD
Join more than 132,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.